Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ)
CNY 5.25
(-2.42%)
CNY 5.25
(-2.42%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 564.68 Million CNY | -5.04% |
| 2022 | 705.68 Million CNY | -23.52% |
| 2021 | 922.69 Million CNY | -16.36% |
| 2020 | 1.1 Billion CNY | -11.55% |
| 2019 | 1.24 Billion CNY | 58.32% |
| 2018 | 787.75 Million CNY | 48.69% |
| 2017 | 529.77 Million CNY | 65.03% |
| 2016 | 321.02 Million CNY | 23.53% |
| 2015 | 259.87 Million CNY | 10.05% |
| 2014 | 236.14 Million CNY | 15.42% |
| 2013 | 204.6 Million CNY | 19.64% |
| 2012 | 171.02 Million CNY | 44.18% |
| 2011 | 118.61 Million CNY | 33.09% |
| 2010 | 89.12 Million CNY | 27.03% |
| 2009 | 70.15 Million CNY | 28.15% |
| 2008 | 54.74 Million CNY | 82.08% |
| 2007 | 30.06 Million CNY | 8.02% |
| 2006 | 27.83 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 147.03 Million CNY | 30.43% |
| 2024 Q3 | 152.6 Million CNY | 10.79% |
| 2024 Q1 | 112.73 Million CNY | -43.2% |
| 2023 Q3 | 131.44 Million CNY | -22.93% |
| 2023 Q4 | 198.46 Million CNY | 50.98% |
| 2023 Q2 | 170.56 Million CNY | 3.77% |
| 2023 FY | 670.1 Million CNY | -5.04% |
| 2023 Q1 | 164.36 Million CNY | -8.45% |
| 2022 Q1 | 162 Million CNY | -44.36% |
| 2022 Q2 | 163.09 Million CNY | 0.67% |
| 2022 Q3 | 201.04 Million CNY | 23.27% |
| 2022 Q4 | 179.53 Million CNY | -10.7% |
| 2022 FY | 705.68 Million CNY | -23.52% |
| 2021 Q4 | 291.16 Million CNY | 42.45% |
| 2021 FY | 922.69 Million CNY | -16.36% |
| 2021 Q2 | 192.77 Million CNY | -17.75% |
| 2021 Q3 | 204.39 Million CNY | 6.03% |
| 2021 Q1 | 234.36 Million CNY | -45.68% |
| 2020 Q2 | 209.83 Million CNY | 19.49% |
| 2020 Q4 | 431.43 Million CNY | 50.72% |
| 2020 Q1 | 175.6 Million CNY | -63.68% |
| 2020 FY | 1.1 Billion CNY | -11.55% |
| 2020 Q3 | 286.24 Million CNY | 36.42% |
| 2019 Q3 | 309.47 Million CNY | 5.04% |
| 2019 FY | 1.24 Billion CNY | 58.32% |
| 2019 Q1 | 159.57 Million CNY | -37.34% |
| 2019 Q2 | 294.62 Million CNY | 84.63% |
| 2019 Q4 | 483.51 Million CNY | 56.24% |
| 2018 FY | 787.75 Million CNY | 48.69% |
| 2018 Q4 | 254.66 Million CNY | 20.05% |
| 2018 Q3 | 212.12 Million CNY | 24.59% |
| 2018 Q2 | 170.25 Million CNY | 12.96% |
| 2018 Q1 | 150.71 Million CNY | -35.57% |
| 2017 Q1 | 69.25 Million CNY | -43.4% |
| 2017 Q3 | 140.3 Million CNY | 62.58% |
| 2017 FY | 529.77 Million CNY | 65.03% |
| 2017 Q4 | 233.92 Million CNY | 66.73% |
| 2017 Q2 | 86.29 Million CNY | 24.61% |
| 2016 FY | 321.02 Million CNY | 23.53% |
| 2016 Q1 | 66.01 Million CNY | -22.54% |
| 2016 Q2 | 60.21 Million CNY | -8.78% |
| 2016 Q3 | 72.43 Million CNY | 20.29% |
| 2016 Q4 | 122.35 Million CNY | 68.9% |
| 2015 Q2 | 54.54 Million CNY | -9.67% |
| 2015 Q1 | 60.38 Million CNY | -8.52% |
| 2015 Q3 | 59.72 Million CNY | 9.51% |
| 2015 FY | 259.87 Million CNY | 10.05% |
| 2015 Q4 | 85.22 Million CNY | 42.69% |
| 2014 Q3 | 57.67 Million CNY | 5.14% |
| 2014 Q4 | 66 Million CNY | 14.45% |
| 2014 Q2 | 54.85 Million CNY | -4.79% |
| 2014 Q1 | 57.61 Million CNY | -6.72% |
| 2014 FY | 236.14 Million CNY | 15.42% |
| 2013 Q4 | 61.76 Million CNY | 28.74% |
| 2013 Q3 | 47.97 Million CNY | 1.52% |
| 2013 Q2 | 47.25 Million CNY | -0.73% |
| 2013 Q1 | 47.6 Million CNY | -13.62% |
| 2013 FY | 204.6 Million CNY | 19.64% |
| 2012 FY | 171.02 Million CNY | 44.18% |
| 2012 Q3 | 40.13 Million CNY | 0.59% |
| 2012 Q2 | 39.9 Million CNY | 11.25% |
| 2012 Q4 | 55.11 Million CNY | 37.31% |
| 2012 Q1 | 35.86 Million CNY | 37.93% |
| 2011 Q2 | 34.47 Million CNY | 24.32% |
| 2011 FY | 118.61 Million CNY | 33.09% |
| 2011 Q1 | 27.72 Million CNY | 19.13% |
| 2011 Q4 | 26 Million CNY | -14.48% |
| 2011 Q3 | 30.4 Million CNY | -11.79% |
| 2010 Q1 | 19.47 Million CNY | -5.01% |
| 2010 Q3 | 22.69 Million CNY | -4.15% |
| 2010 Q4 | 23.27 Million CNY | 2.56% |
| 2010 FY | 89.12 Million CNY | 27.03% |
| 2010 Q2 | 23.67 Million CNY | 21.59% |
| 2009 FY | 70.15 Million CNY | 28.15% |
| 2009 Q4 | 20.5 Million CNY | 1.78% |
| 2009 Q3 | 20.14 Million CNY | 20.01% |
| 2009 Q2 | 16.78 Million CNY | 31.82% |
| 2009 Q1 | 12.73 Million CNY | -28.3% |
| 2008 FY | 54.74 Million CNY | 82.08% |
| 2008 Q4 | 17.75 Million CNY | 41.0% |
| 2008 Q3 | 12.59 Million CNY | 0.0% |
| 2007 FY | 30.06 Million CNY | 8.02% |
| 2006 FY | 27.83 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 1.36 Billion CNY | 58.6% |
| Zhejiang Zhenyuan Share Co., Ltd. | 654.18 Million CNY | 13.681% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | 548.76 Million CNY | -2.901% |
| Hubei Guangji Pharmaceutical Co., Ltd. | 343.25 Million CNY | -64.511% |
| Yifan Pharmaceutical Co., Ltd. | 2.82 Billion CNY | 80.039% |
| Guangdong Jiaying Pharmaceutical Co., Ltd | 307.2 Million CNY | -83.815% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 7.5 Billion CNY | 92.48% |
| Boai NKY Medical Holdings Ltd. | 309.15 Million CNY | -82.657% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 463.02 Million CNY | -21.956% |